CHI-LING CHENLai, Chao-ChihChao-ChihLaiLuh, Dih-LingDih-LingLuhChuang, Shao-YuanShao-YuanChuangKUEN-CHEH YANGYeh, Yen-PoYen-PoYehMing-Fang Yen, AmyAmyMing-Fang YenKING-JEN CHANGRAY-E CHANGLi-Sheng Chen, SamSamLi-Sheng Chen2021-07-072021-07-072021-060929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/570517The spread of the emerging pathogen, named as SARS-CoV-2, has led to an unprecedented COVID-19 pandemic since 1918 influenza pandemic. This review first sheds light on the similarity on global transmission, surges of pandemics, and the disparity of prevention between two pandemics. Such a brief comparison also provides an insight into the potential sequelae of COVID-19 based on the inference drawn from the fact that a cascade of successive influenza pandemic occurred after 1918 and also the previous experience on the epidemic of SARS and MERS occurring in 2003 and 2015, respectively. We then propose a systematic framework for elucidating emerging infectious disease (EID) such as COVID-19 with a panorama viewpoint from natural infection and disease process, public health interventions (non-pharmaceutical interventions (NPIs) and vaccine), clinical treatments and therapies (antivirals), until global aspects of health and economic loss, and economic evaluation of interventions with emphasis on mass vaccination. This review not only concisely delves for evidence-based scientific literatures from the origin of outbreak, the spread of SARS-CoV-2 to three surges of pandemic, and NPIs and vaccine uptakes but also provides a new insight into how to apply big data analytics to identify unprecedented discoveries through COVID-19 pandemic scenario embracing from biomedical to economic viewpoints.en1918 influenza pandemic; COVID-19; Clinical management; Containment strategy; Economic evaluation[SDGs]SDG3antivirus agent; SARS-CoV-2 vaccine; adult respiratory distress syndrome; antiviral therapy; China; clinical evaluation; coronavirus disease 2019; drug efficacy; economic evaluation; epidemic; evidence based practice; global disease burden; household; human; Middle East respiratory syndrome; pandemic; pneumonia; Review; severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; social distancing; Spanish influenza; Taiwan; virus transmission; cost benefit analysis; influenza; pandemic; Cost-Benefit Analysis; COVID-19; Humans; Influenza, Human; Pandemics; SARS-CoV-2review10.1016/j.jfma.2021.05.022341168962-s2.0-85107656866https://api.elsevier.com/content/abstract/scopus_id/85107656866